Dr. Moyle joined Spaltudaq as Senior Vice President and Chief Development Officer in May, 2007. He has more than seventeen years of industry experience in drug discovery and development of biologics and small molecules. Prior to joining Spaltudaq, Dr. Moyle was Vice President of Research and Corporate Officer at Tanox, a Houston-based public biotech company specializing in monoclonal antibody therapeutics, where he built a successful product pipeline including three antibody candidates that have advanced to development thus far. Before Tanox, Dr. Moyle headed the Expression Profiling & Pharmacogenomics department at Amgen, which included responsibility for building and running the company’s high-throughput microarray facility. Before that, he was a Group Leader at Corvas (now Dendreon), where he co-discovered two novel natural product biologics that were partnered with Pharma and subsequently advanced to pivotal clinical trials. Dr. Moyle was a postdoctoral scientist at Genentech where he was part of the company’s first program in small molecule therapeutics. He earned a Ph.D. and B.Sc. in Biochemistry at the University of Toronto, and has more than 40 publications and issued US patents.